EWTX

Edgewise Therapeutics, Inc. is a muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The Company is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.

Wall Street analysts forecast EWTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EWTX is 37.00 USD with a low forecast of 20.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Edgewise Therapeutics Inc revenue for the last quarter amounts to -46.86M USD, increased 15.89 % YoY.

Edgewise Therapeutics Inc. EPS for the last quarter amounts to -34865000.00 USD, increased 24.99 % YoY.

Edgewise Therapeutics Inc (EWTX) has 110 emplpoyees as of December 16 2025.

Today EWTX has the market capitalization of 2.53B USD.